Ahmad Sadr - Apellis Pharmaceuticals Senior Vice President -Technical Operations
| APLS Stock | USD 47.84 2.02 4.05% |
President
Mr. Ahmad Sadr is Senior Vice President Technical Operations of the Company. He has served as our Senior Vice President Technical Operations since April 2019, having served as our Vice President Technical Operations from January 2017 to April 2019. From May 2016 to January 2017 he served as Director Outsourced Manufacturing at Portola Pharmaceuticals, a public biotechnology company, leading critical aspects of outsourced drug substance manufacturing. From April 2015 to May 2016 he served as Vice President Technical Operations at Vision Medicines, a private biotechnology company, and from December 2004 to April 2015 he held various leadership roles in manufacturing and supply chain at Genentech, a public biotechnology company, including as Associate Director, Manufacturing Science and Technology from June 2014 to April 2015 and Associate Director, Global External Manufacturing from February 2012 to June 2014, with responsibility for global manufacturing of development and commercial stage biologics and pharmaceutical drugs since 2019.
| Age | 44 |
| Tenure | 5 years |
| Address | 100 Fifth Avenue, Waltham, MA, United States, 02451 |
| Phone | 617 977 5700 |
| Web | https://www.apellis.com |
Apellis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4173) % which means that it has lost $0.4173 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9014) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.7 in 2024. Return On Capital Employed is likely to drop to -1 in 2024. At this time, Apellis Pharmaceuticals' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 205.1 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 18.2 M in 2024.Similar Executives
| Found 10 records | PRESIDENT Age | ||
| Rebecca Taub | Madrigal Pharmaceuticals | 66 | |
| Erin MD | Terns Pharmaceuticals | 53 | |
| Marc Schneebaum | Madrigal Pharmaceuticals | 64 | |
| Kelly Carranza | Acumen Pharmaceuticals | N/A | |
| Fouad MD | Blueprint Medicines Corp | 55 | |
| Christopher Murray | Blueprint Medicines Corp | 60 | |
| Wendy Rieder | Madrigal Pharmaceuticals | 46 | |
| James Doherty | Acumen Pharmaceuticals | 56 | |
| Tracey McCain | Blueprint Medicines Corp | 50 | |
| Anthony Boral | Blueprint Medicines Corp | 55 | |
Management Performance
| Return On Equity | -2.9 | ||||
| Return On Asset | -0.42 |
Apellis Pharmaceuticals Leadership Team
Elected by the shareholders, the Apellis Pharmaceuticals' board of directors comprises two types of representatives: Apellis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apellis. The board's role is to monitor Apellis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Apellis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apellis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Geffken, Interim CFO | ||
| Nur Nicholson, Chief Officer | ||
| Ahmad Sadr, Senior Vice President -Technical Operations | ||
| Lucia Celona, Chief People Officer | ||
| Pr MD, Head Board | ||
| Gerald Chan, Chairman of the Board | ||
| David Watson, General Counsel, Vice President of Corporate Development | ||
| Lukas MD, Chief Officer | ||
| Victoria Brown, Senior President | ||
| Lukas Scheibler, Executive Vice President - Research and Development | ||
| Timothy Sullivan, CFO, Treasurer | ||
| Cedric MD, President, CoFounder | ||
| Nicole Perry, Vice President - Finance | ||
| Meredith Kaya, Investor President | ||
| Alec Machiels, Co-Founder, Director | ||
| Adam Townsend, Chief Commercial Officer | ||
| Thomas Lackner, Senior Vice President Head of Europe | ||
| James CPA, Corporate VP | ||
| Karen Lewis, Chief Officer | ||
| JD Esq, General Counsel | ||
| MBA JD, CoFounder Director | ||
| Stephanie OBrien, Director | ||
| Sinclair Dunlop, Director | ||
| Cedric Francois, President CEO, Co-Founder, Director | ||
| David Acheson, Senior Commercial | ||
| Mark Delong, Chief Officer | ||
| Federico MD, CoFounder Officer | ||
| Pascal Deschatelets, CoFounder Officer | ||
| Federico Grossi, Vice President - Clinical Development | ||
| Jeffrey Eisele, Chief Officer | ||
| Steven Axon, Chief Business Officer |
Apellis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Apellis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.9 | ||||
| Return On Asset | -0.42 | ||||
| Profit Margin | (1.33) % | ||||
| Operating Margin | (0.58) % | ||||
| Current Valuation | 5.77 B | ||||
| Shares Outstanding | 120.58 M | ||||
| Shares Owned By Insiders | 13.22 % | ||||
| Shares Owned By Institutions | 95.93 % | ||||
| Number Of Shares Shorted | 10.67 M | ||||
| Price To Earning | (6.94) X |
Apellis Pharmaceuticals Investors Sentiment
The influence of Apellis Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Apellis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Apellis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Apellis. The trend in average sentiment can be used to explain how an investor holding Apellis can time the market purely based on public headlines and social activities around Apellis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Apellis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Apellis Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Apellis Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Apellis Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Apellis Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Apellis Pharmaceuticals' short interest history, or implied volatility extrapolated from Apellis Pharmaceuticals options trading.
Pair Trading with Apellis Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Apellis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Apellis Stock
| 0.81 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
| 0.63 | VTRS | Viatris Earnings Call This Week | PairCorr |
| 0.66 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.71 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
Moving against Apellis Stock
| 0.76 | HCM | HUTCHMED DRC | PairCorr |
| 0.71 | ACB | Aurora Cannabis Downward Rally | PairCorr |
| 0.67 | CGC | Canopy Growth Corp Downward Rally | PairCorr |
| 0.62 | FLGC | Flora Growth Corp Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Apellis Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Apellis Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Apellis Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Apellis Pharmaceuticals to buy it.
The correlation of Apellis Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Apellis Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Apellis Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Apellis Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apellis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Apellis Stock analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.45) | Revenue Per Share 3.342 | Quarterly Revenue Growth 5.459 | Return On Assets (0.42) | Return On Equity (2.90) |
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apellis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.